Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Children's Oncology Group
Milton S. Hershey Medical Center
Massachusetts General Hospital
University of Florida
Children's Oncology Group
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
National Cancer Institute (NCI)
University of Iowa
Children's Oncology Group
University of Colorado, Denver
Wake Forest University Health Sciences
University of Iowa
Pediatric Brain Tumor Consortium
University of Iowa
National Cancer Institute (NCI)
Duke University
University of Iowa
Memorial Sloan Kettering Cancer Center
Stanford University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Novartis
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Pfizer
Eli Lilly and Company